Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025
Corvus Pharmaceuticals (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has scheduled its second quarter 2025 financial results and business update conference call for August 7, 2025 at 4:30 pm ET.
Investors can access the call via telephone at 1-800-717-1738 (domestic) or 1-646-307-1865 (international). A live webcast will be available through the company's investor relations website, with a replay accessible for 90 days following the presentation.
Corvus Pharmaceuticals (NASDAQ: CRVS), un'azienda biofarmaceutica in fase clinica, ha programmato la conference call per la presentazione dei risultati finanziari del secondo trimestre 2025 e l'aggiornamento aziendale per il 7 agosto 2025 alle 16:30 ET.
Gli investitori potranno partecipare alla chiamata telefonando al 1-800-717-1738 (nazionale) o al 1-646-307-1865 (internazionale). Una diretta web sarà disponibile tramite il sito web delle relazioni con gli investitori della società, con la possibilità di rivedere la registrazione per 90 giorni dopo la presentazione.
Corvus Pharmaceuticals (NASDAQ: CRVS), una compañía biofarmacéutica en etapa clínica, ha programado su conferencia telefónica para presentar los resultados financieros del segundo trimestre de 2025 y una actualización empresarial para el 7 de agosto de 2025 a las 4:30 pm ET.
Los inversores pueden acceder a la llamada telefónica marcando al 1-800-717-1738 (nacional) o al 1-646-307-1865 (internacional). Habrá una transmisión en vivo disponible a través del sitio web de relaciones con inversionistas de la compañía, con una repetición accesible durante 90 días después de la presentación.
Corvus Pharmaceuticals (NASDAQ: CRVS)는 임상 단계의 바이오제약 회사로, 2025년 2분기 재무 실적 및 사업 업데이트 컨퍼런스 콜을 2025년 8월 7일 오후 4시 30분 ET에 예정했습니다.
투자자들은 국내 전화 1-800-717-1738 또는 국제 전화 1-646-307-1865를 통해 콜에 참여할 수 있습니다. 회사의 투자자 관계 웹사이트에서 실시간 웹캐스트가 제공되며, 발표 후 90일간 다시보기 서비스를 이용할 수 있습니다.
Corvus Pharmaceuticals (NASDAQ : CRVS), une entreprise biopharmaceutique en phase clinique, a programmé sa conférence téléphonique pour les résultats financiers du deuxième trimestre 2025 et la mise à jour commerciale le 7 août 2025 à 16h30 ET.
Les investisseurs peuvent accéder à l'appel par téléphone au 1-800-717-1738 (national) ou au 1-646-307-1865 (international). Un webcast en direct sera disponible via le site des relations investisseurs de la société, avec un replay accessible pendant 90 jours après la présentation.
Corvus Pharmaceuticals (NASDAQ: CRVS), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Telefonkonferenz zur Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 und ein Geschäftsupdate für den 7. August 2025 um 16:30 Uhr ET angesetzt.
Investoren können die Telefonkonferenz unter der Nummer 1-800-717-1738 (national) oder 1-646-307-1865 (international) verfolgen. Ein Live-Webcast wird über die Investor-Relations-Website des Unternehmens verfügbar sein, mit einer Wiedergabe, die 90 Tage nach der Präsentation abrufbar ist.
- None.
- None.
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 7, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2025 financial results.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
When will Corvus Pharmaceuticals (CRVS) report Q2 2025 earnings?
How can investors access Corvus Pharmaceuticals' Q2 2025 earnings call?
How long will Corvus Pharmaceuticals' Q2 2025 earnings webcast be available?
What will be discussed in Corvus Pharmaceuticals' upcoming conference call?
